Continued Access to PREVAIL (CAP2)

This study aims to provide additional information about the safety and efficacy of the WATCHMAN Left Atrial Appendage Closure Technology

Heart & Vascular - Interventional Cardiology Trials
Paul Huang, MD

Men and women 18 years of age or older, who have documented paroxysmal, persistent, or permanent nonvalvular atrial fibrillation, and are eligible for long-term warfarin therapy, but do not require long-term warfarin therapy.

Inger Rasmussen